Gilead Sciences (NASDAQ:GILD) had its price target lowered by analysts at Royal Bank Of Canada from $105.00 to $100.00. They now have a "sector perform" rating on the stock.
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $110.00 to $115.00. They now have a "neutral" rating on the stock.
Hopping Mad Over Drug Company Product Hopping [Forbes]
Gilead Sciences (NASDAQ:GILD) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Genetic Modification Therapies Set to Surge, Market Valued at $32.1 Billion by 2030 [Yahoo! Finance]